Medline Inc. is 28.4x more valuable than Pulse Biosciences, Inc. by market capitalization ($49.12 B vs $1.73 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | PLSE | MDLN |
|---|---|---|
| Market cap | $1.73 B | $49.12 B |
| US-listed rank | #2212 | #322 |
| Revenue (latest FY) | $350.00K | $28.43B |
| Net income (latest FY) | -$72.78M | $1.16T |
| Net margin | -20794.6% | 4069.4% |
| P/E (trailing FY) | - | 0.0 |
| SEC filings | 616 | 103 |
Medline Inc. is 28.4x more valuable than Pulse Biosciences, Inc. by market capitalization ($49.12 B vs $1.73 B).
In their latest fiscal years, Pulse Biosciences, Inc. reported $350.00K in revenue while Medline Inc. reported $28.43B.
Full pages: Pulse Biosciences, Inc. and Medline Inc., or browse the full rankings.